GeneDx Holdings WGS Self-pay patients — Total Revenue

Similar metrics at other companies

SGRYSelf-pay — Revenue

$19.2M-4.5%

SEMTotal patient services revenues — Revenue

$1.28B+4.8%

RDNTOther payors — Total consolidated revenues

$33.59M+21.3%

IRTCNon-contracted third-party payors — Revenue, net

$11.04M+9.4%

SGRYSelf-pay — Revenue by service type as a proportion of total revenues (percent)

2.4%-0.3pp

SEMNon-Medicare — Revenue

$842.05M+1.5%

Questions, answered.

What is GeneDx Holdings's self-pay patients — total revenue?

GeneDx Holdings (WGS) reported self-pay patients — total revenue of $286K in Q1 2026.

How has GeneDx Holdings's self-pay patients — total revenue changed year-over-year?

GeneDx Holdings's self-pay patients — total revenue increased by 197.9% year-over-year, from $96K to $286K.

What is the long-term trend for GeneDx Holdings's self-pay patients — total revenue?

Over 4 years (2021 to 2025), GeneDx Holdings's self-pay patients — total revenue has grown at a -23.9% compound annual growth rate (CAGR), from $4.06M to $1.36M.

What does self-pay patients — total revenue mean?

This metric represents the total gross revenue generated from diagnostic testing services provided to patients who pay directly for services rather than through third-party insurance providers. It serves as a key indicator of the company's ability to capture market share in the direct-to-consumer or uninsured patient segments. Monitoring this revenue stream helps assess the demand for specialized diagnostic offerings outside of traditional reimbursement channels.